



Towards Excellence in Quality IPA Annual Conference 23rd February 2016

Gerald Heddell

Director, Inspection, Enforcement and Standards




The success of Indian Pharma



- 10% of world's drugs (by volume)
- 12-17% annual pharmaceutical growth rate (~\$20B in 2015)
- PharmaVision 2020 –"end to end" leader
- "Make in India"
 - incentives for bulk drug manufacture
 - >\$200B spend on medical infrastructure
 - New pharmaceutical parks

India – "Pharmacy of the World"





2015 'High impact' inspection findings

Compliance Management Failing PQS

Risk based investigations and actions

Personnel knowledge / experience

Documentation issues

Common themes; increasing severity

2015 'High impact' inspection findings

Inspection Action Group

Compliance Management

Failing PQS

Mgmt oversight and resourcing – ICH Q10

Quality defect investigations and actions

Operational cross contamination controls

Failing PQS

Risk based investigations and actions

Personnel knowledge / experience


Documentation issues

Common themes; increasing severity

2015 'High impact' inspection findings



2015 'High impact' inspection findings



Challenges to be faced:

- ➤ No compromise on Quality
- Ongoing austerity
- Global population changes (ageing, co-morbidities, polypharmacy, chronic conditions)
- > Transparency and communications
- Opportunities for use of Real World Data
- Internet and illegal supply

Opportunities yet to be realised:

- World leader in biosimilars?
- World leader in drug discovery and development? (currently only ~2% of global trials in India)
- Innovative biologicals (from domestic products)
- Personalised medicines/Genomics
- Companion diagnostics
- Increased automation and efficiency
- Use of Real World Data

Excellence in Quality?



"Individual efforts can bring excellence but only collective efforts can deliver effectively"

THANK YOU FOR YOUR ATTENTION

Gerald W Heddell

Director

+44 (0) 203 080 6500 gerald.heddell@mhra.gsi.gov.uk

© Crown Copyright 2016

About copyright

All material created by the Medicines and Healthcare products Regulatory Agency, including materials featured within these MHRA presentation notes and delegate pack, is subject to Crown copyright protection. We control the copyright to our work (which includes all information, database rights, logos and visual images), under a delegation of authority from the Controller of Her Majesty's Stationery Office (HMSO).

The MHRA authorises you to make one free copy, by downloading to printer or to electronic, magnetic or optical storage media, of these presentations for the purposes of private research, study and reference. Any other copy or use of Crown copyright materials featured on this site, in any form or medium is subject to the prior approval of the MHRA.

Further information, including an application form for requests to reproduce our material can be found at www.mhra.gov.uk/crowncopyright

Material from other organisations

The permission to reproduce Crown copyright protected material does not extend to any material in this pack which is subject to a separate licence or is the copyright of a third party. Authorisation to reproduce such material must be obtained from the copyright holders concerned.